The IN8bio Mission

IN8bio was founded with the mission of developing novel therapies to address cancer. The company focuses on the development of cellular therapies using gamma-delta T cells, the “unconventional” T cell and is advancing a pipeline of autologous, allogeneic and genetically modified product candidates for both liquid and solid tumors.

We are the first company to advance genetically modified gamma-delta T cells into the clinic, leveraging the powerful and naturally occurring anti-cancer properties of these cells to enable their use in combination with therapeutic administration of chemotherapy.

IN8bio is located in New York City with its primary scientific operations in Birmingham, Alabama.